Dilution profile // every instrument, one screen, from SEC filings

Ainos, Inc. (AIMDW)

CIK 1014763 · all EDGAR filings →

Overall dilution risk
HIGHworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
HIGHS-3/A on file 2024-12-30
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
LOWwarrants = 5% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
LOW-64% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
a reverse-split-sized cliff is in this window; read the chart
Cash need
HIGH~3.7 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2020-08-122026-08-03

Latest: 7.4M shares as of Aug 3, 2026 (10-Q). Share count fell from 144.4M to 19.5M between May 16, 2022 and Aug 12, 2022, a pattern consistent with a reverse split (roughly 1-for-7); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

TrancheWarrantsExercise priceTermNotes
Lind Warrant240,388$10.8
ASE Warrant100,000$22.5
Public Warrant35,880$106.25
Placement Agent Warrant4,125$41.255y
Representative Warrant1,560$116.875
Private Warrantnot taggednot tagged5y

Tranches exactly as the company dimensioned them in its 10-Q filed Aug 3, 2026. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Warrants outstanding: 381,953 underlying shares, as reported Jun 30, 2026 (10-Q).

Balance-sheet fair value of warrants: $2.2M as of Dec 31, 2012.

Rough fully diluted estimate: 7.8M = 7.4M O/S + 381,953 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

NotePrincipalCarryingConv. priceRateIf converted
March Two Thousand Twenty Six Convertible Notes$90.0Mnot tagged
March Two Thousand Twenty Five Convertible Notes$3.0Mnot tagged
Loan Agreementnot tagged$2.8Mnot tagged
Lee Note$1.0M$22.5~44,444 sh
ASE Notenot tagged$37.5

If every note above converted at its tagged price: ~44,444 new shares on 7.4M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.

Notes exactly as the company dimensioned them in its 10-Q filed Aug 3, 2026. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding7.4MAug 3, 2026
+ Lind Warrant (if exercised)240,388Jun 30, 2026
+ ASE Warrant (if exercised)100,000Jun 30, 2026
+ Public Warrant (if exercised)35,880Jun 30, 2026
+ Placement Agent Warrant (if exercised)4,125Jun 30, 2026
+ Representative Warrant (if exercised)1,560Jun 30, 2026
+ Lee Note (if fully converted)44,444Mar 13, 2023
Fully diluted estimate7.8M+5.8% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Dec 23, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-3May 31, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-1Apr 8, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 3 executed · 0 registered.

EXECUTEDJul 24, 2026Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDDec 31, 2025Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDSep 5, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EFFECTIVEDec 31, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDDec 30, 2024S-3/A registration — capacity to sell shares, not a sale yetS-3/A
REGISTEREDDec 23, 2024S-3 registration — capacity to sell shares, not a sale yetS-3
EXECUTEDAug 9, 2024Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDJul 11, 2024Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EFFECTIVEJun 11, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDMay 31, 2024S-3 registration — capacity to sell shares, not a sale yetS-3
EFFECTIVEApr 16, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDApr 8, 2024S-1 registration — capacity to sell shares, not a sale yetS-1

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full AIMDW workspace